entertainment -WSS

entertainment

author：explore 2025-09-29 18:17:22 - browse：9

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Ambulance rides for just $100? Advisers want major billing fixes

hotspot

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Biden’s NIH nominee is languishing in Congress

White House calls on federal agencies to crack down on AI abuses

MoonLake credibility takes another hit with mid

Medicare wants to send $9 billion to 340B hospitals

Biotech incubator Curie.Bio graduates its first startup

hotspot

entertainment

leisure time

Apple is now the first public company to be valued at $3 trillion

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Psychedelics group wrestles with new pharma identity

Sanofi CEO defends move to abandon profit guidance, boost research

The cancer drug shortage isn’t new — and neither are the solutions

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Drug repurposing or repositioning? The language matters

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Psychedelics group wrestles with new pharma identity

Biotech incubator Curie.Bio graduates its first startup

focus

Wisconsin governor employs partial veto to fund schools for 4 centuries

Study: New antibiotic targets gonorrhea as well as last existing drug

Senate panel clears PBM, hopsital reforms

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

hotspot

focus

entertainment

hotspot